Therefore, PPAR-γ expression stimulants not only accelerate the inhibition of NF-κB DNA-binding activity, but also suppress the acute phase of neuroinflammation mediated by IL-6; this suggests that it could be a promising therapeutic strategy in most brain disorders [46]. This evidence concerns the gene NFKB1 and brain disorder.